CN1517026A - Milk powder capable of regulating blood pressure - Google Patents
Milk powder capable of regulating blood pressure Download PDFInfo
- Publication number
- CN1517026A CN1517026A CNA03100380XA CN03100380A CN1517026A CN 1517026 A CN1517026 A CN 1517026A CN A03100380X A CNA03100380X A CN A03100380XA CN 03100380 A CN03100380 A CN 03100380A CN 1517026 A CN1517026 A CN 1517026A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- milk
- leu
- powder
- blood pressure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A milk powder for regulating blood pressure is prepared from high-quality fresh milk, bioactive short-chain lectoprotein polypeptide, VE, and bifidobacterium reproduction factor-oligofructose.
Description
Invention field
The present invention relates to a kind of with health rolely,, be called again and press happy milk powder as regulating the milk powder of blood pressure effect.
Background technology
Many health products are arranged in the market, but also be not primarily aimed at hyperpietic's product.Hypertension be vessel retraction press be elevated to certain level with diastolic pressure and cause health is made a difference or a kind of symptom of disease takes place.The elderly of China present nearly 1/2nd suffers from hypertension in various degree, and wherein about 60% patient's blood pressure is in the scope of 140-160/90-95mmHg.The blood pressure of normal body in one day 24h is not changeless.Sports, manual labor, stress, excited, smoking and when cold blood pressure temporary rising can appear, and tranquil, have a rest or during sleep blood pressure can return to original level or lower.
Hypertension is divided two kinds of primary and Secondary cases by occurrence cause, primary hypertension patient accounts for about 90% of sum, is likely because multiple factor causes, comprises heredity, sex, age, obesity, diet and environmental factor etc.Secondary hypertension only accounts for about 10% of sum, and its treatment should be eliminated earlier and cause the hypertensive cause of disease, and hypertension symptom can be died away.Suffer from hypertension time one length and can have a strong impact on the vitals such as heart, brain, kidney of body.As symptoms such as hypertension may to cause that heart rate depletion, atherosclerotic, the cerebrovascular are blocked or cerebral blood vessel breaks hemorrhage, apoplexy, renal failures.Vascular hypertension more and more becomes the disease of worldwide harm humans health, and searching is effective more, littler medicine and the health products of side effect have been various countries pharmacy man and Food Engineering Development personnel's target.
In recent years, domestic and international many scholars isolate the polypeptide of many biologically actives from protein such as breast, fish, vegetable protein, some of them peptide class has inhibition tonin (AngiotensinI-converting Enzyme, ACE) activity, thus can play hypotensive function.Therefore blood pressure lowering peptide is considered to a kind of natural functional step-down good merchantable brand that is perfectly safe.
Summary of the invention
The present invention is to be raw material with the milk protein, is primarily aimed at hyperpietic's physilogical characteristics and healthy needs, and the employing modern biotechnology carries out the development and the exploitation of functional blood pressure lowering peptide dairy products.Milk protein is to carry out enzyme hydrolysis by casein or lactalbumin, obtains the peptide of biologically active---blood pressure lowering peptide.People such as Maruyama studies show that, are positioned at α
123-34 in the-casein primary structure sequence, the 177-183 peptide Duan Junke of 23-27 and 194-199 amino acid residue and cattle beta-casein suppresses the activity of ACE.The in vitro test that people such as Kohmura carry out is found, peptide section that the 39-52 amino acid residue of human milk beta-casein is formed and the 63-65 peptide section in human milk κ-casein also have the effect that suppresses the ACE activity, wherein tool activity be the peptide section that the 43-52 amino acid residue of human milk beta-casein is formed, this peptide section also has activity in vivo, they have synthesized the peptide section of being made up of 23 amino acid in the peptide section of being made up of 69 amino acid in the human milk beta-casein and the human milk κ-casein, and have the function that suppresses the ACE activity.Maruyama, S. etc. (1987) have also obtained some by the hydrolysis to the cow's milk alpha-casein and have had the polypeptide that suppresses the ACE activity., therefore can cause the rising of blood pressure because but the ACE passivation has the bradykinin (Bradikynin) of vasodilator effect.And blood pressure lowering peptide can suppress the activity of ACE, thereby plays hypotensive function.
Therefore, research to blood pressure lowering peptide food, hypertensive prevention and treatment are had broad application prospects, it helps the upgrading of dairy products product, this novel health functional food can be described as a kind of natural functional step-down good merchantable brand that is perfectly safe, and its exploitation has huge economic benefit and theory significance.Since the screening of bacterial strain with and the ability of the protease that produced be the key technology that influences final blood pressure lowering peptide concentration, so the core of this research utilizes cow's milk to be raw material exactly, produce blood pressure lowering peptide by lactoalbumin hydrolysate, produce milk powder with buck functionality through scientific matching, when making product have abundant nutrition, increased hypotensive health care again, reach advanced world standards with this research that drives our province and even China's association area, promote novel development with antihypertensive product of health care.
The happy milk powder of pressure of the present invention comprises with the milk powder gross weight being the following raw material of benchmark:
Fresh milk 260～720 weight portions
Hypotensive protein hydrolysate 0.1～40 weight portion
Vitamin E 0.001～0.05 weight portion
Whey powder 0～30 weight portion
Dextrine powder 0～20 weight portion
Maltose 0～10 weight portion
Refined oil 0～5 weight portion
Palm oil 0～5 weight portion
Calcium powder 0～5 weight portion
Potassium citrate 0～10 weight portion
Vitamin and trace element 0～an amount of
FOS (clean thing) 0～2 weight portion
Perhaps above-mentioned fresh milk can use 30-80 weight portion milk powder (promptly the milk powder that is directly obtained by cow's milk does not contain other additive) to replace.
Powdered milk composition of the present invention preferably includes:
Fresh milk 260～720 weight portions
Hypotensive protein hydrolysate 1～20 weight portion
Vitamin E 0.1～0.03 weight portion
Whey powder 0～30 weight portion
Dextrine powder 0～20 weight portion
Maltose 0～10 weight portion
Refined oil 0～5 weight portion
Palm oil 0～5 weight portion
Calcium powder 0～5 weight portion
Potassium citrate 0～10 weight portion
Vitamin and trace element are an amount of
FOS (clean thing) 0.01～2 weight portion
Perhaps above-mentioned fresh milk can use 30-80 weight portion milk powder (i.e. the milk powder that is directly obtained by cow's milk) to replace.
Wherein vitamin comprises vitamin A, vitamin B1, B2, B6 and B12, vitamin C, vitamin D etc.Trace element comprises calcium, phosphorus, iron etc., and they can conventional amount used exist.
Can above-mentioned prescription be processed into milk powder by the conventional method of this area.
A kind of method for optimizing comprises that various raw materials are allocated in the preheating sterilization with the purification of raw material cow's milk, homogeneous, and vacuum concentrates, spray-drying, cooling and packing.
Prescription of the present invention is according to the elderly's physilogical characteristics and nutritional need, adopt modern biological enzymolysis technology the proteolysis in the cow's milk to be become the polypeptide of the biologically active of short chain, be more conducive to the elderly's digestion and absorption, this mainly is because middle-aged and old increase along with the age, its GI digestion and absorption function also goes down thereupon, and polypeptide is owing to be little molecule, can directly be absorbed after arriving enteron aisle, therefore required protein the elderly's every day can be replenished fast, and the effect of antifatigue can be played.
This product is owing to can produce the polypeptide that some have buck functionality simultaneously in the proteolysis process, these polypeptide mainly are the activity that suppresses angiotoninase (ACE), under normal circumstances, hypertensive formation is relevant with the adjusting of hormone in vivo, as: the tensity of hormone systems such as norepinephrine, adrenaline, angiotensins control blood vessel.Essential hypertension may be because due to these system's generation obstacles.The ACE enzyme mainly is to promote that in human body angiotensin I is transformed into Angiotensin II, and the latter be so far known to the strongest sensitizing factor.
The polypeptide that is contained in this product is not a certain single peptide material, but the multiple peptide matters that from hydrolytic process, obtains, as: Ser-Ala-Pro, Met-Lys-Gly, Ala-Leu-Pro-Met-His, Leu-Ile-Val-Thr-Gln, Val-Ser-Leu-Pro-Glu-Trp, Ile-Asp-Tyr-Trp-Leu, Leu-Lys-Pro-Thr-Pro-Glu-Gly-Asp-Leu-Glu-Ile-Leu, Leu-Lys-Gly-Tyr-Gly-Gly-Val-Ser-Leu-Pro-Glu-Ser.
These peptide matters all have the effect that suppresses angiotensins ACE enzymatic activity, can suppress angiotensin I and be converted into Angiotensin II, suppress hypertensive generation, thereby the blood pressure weighing apparatus that guarantees human body is fixed.
And this kind product is unfavorable for that the low crowd of blood pressure is edible.
Embodiment
Come further to set forth the present invention by the following examples.It should be understood that these embodiment never constitute any limitation of the invention.It will be apparent to those skilled in that, under situation without departing from the spirit and scope of the present invention, can make some variations and modification, these variations and modification intention are included in the category of the present invention.
Embodiment 1
1, the purchase of raw milk
Should carry out strict check to the quality of raw milk, inspection content comprises:
A, organoleptic indicator:
B, physical and chemical index:
C, microbiological indicator:
The every index and the method for inspection should be carried out by national GB 6914-86 standard.
2, clean breast
500 weight portion cow's milk purify the rear impurity degree less than 0.5ppm through milk clarifier.
3, preheating sterilization
Breast behind the clean breast carries out 73 ℃ of sterilizations 15 seconds through the syllogic heat exchanger, makes the Ruzhong bacterium reach the scope of regulation.
4, batching
The hypotensive protein hydrolysate powder of 10 weight portions water is heated to 60 ℃, stirs 10 minutes.With 0.01 weight portion vitamin E, an amount of B B-complex and composite trace element, 0.2 weight portion calcium powder melt with warm water respectively, and 1 weight portion FOS dilutes with warm water.After heat-recovery section cools to the breast of (40-45) ℃ prepares burden, the method can reduce the sterilization temperature before concentrating with sterilization, can also guarantee the preservation of multivitamin and trace element in the brew of formula powder and the product.
5, homogeneous
Under the condition of (40-45) ℃, (18-20) MPa, carry out homogeneous, guarantee the homogeneity of product, improve the digestibility of product.
6, vacuum concentrates
Material behind the homogeneous enters cold boiler and reduces pressure concentratedly, removes Ruzhong most of moisture (about 65%), is beneficial to product quality and reduces production costs, economic benefits and social benefits sterilization temperature (80-83) ℃, 24 seconds time, material outlet concentration 16Be '.
7, spray-drying
150 ℃ of technological parameter EATs, 80 ℃ of temperature of outgoing airs, atomisation pressure (10-15) MPa.
8, sieve powder bean jelly
The milk powder that spray-drying is good should be sent the outer and cooling in time of hothouse rapidly, and the overlong time that keeps from heat influences product quality.The reciprocating sieve aerofoil can be separated big powder agglomates, with acquisition homogeneous granules milk powder, and the milk powder temperature is cooled to below 50 ℃.
9, the inspection of semifinished product
Powder after sieving carries out the semi-finished product sampling, carries out physics and chemistry and Micro biological Tests, enters next procedure under qualified situation.
10, Packing of Dried Milk
The Packing of Dried Milk technological process is:
Weighing → fill adds → exhaust → and seal → case → packaging and warehousing
11, product inspection
Finished product will carry out strict physics and chemistry and microbiological analysis, and leave the product report by the batch sampling of central laboratory.
12, the product accord with Q/WDS 045-2002 standard of dispatching from the factory, and have product return on qualification folk prescription to dispatch from the factory.
Embodiment 2
1, the purchase of raw milk
Should carry out strict check to the quality of raw milk, inspection content comprises:
A, organoleptic indicator:
B, physical and chemical index:
C, microbiological indicator:
The every index and the method for inspection should be carried out by national GB 6914-86 standard.
2, clean breast
500 weight portion cow's milk purify the rear impurity degree less than 0.5ppm through milk clarifier.
3, preheating sterilization
Breast behind the clean breast carries out 73 ℃ of sterilizations 15 seconds through the syllogic heat exchanger, makes the Ruzhong bacterium reach the scope of regulation.
4, batching
The hypotensive protein hydrolysate powder of 5 weight portions water is heated to 60 ℃, stirs 10 minutes.0.006 weight portion microorganism E, 1 weight portion calcium powder are melted with warm water respectively, and 0.05 weight portion FOS dilutes with warm water.After heat-recovery section cools to the breast of (40-45) ℃ prepares burden, the method can reduce the sterilization temperature before concentrating with sterilization.
5, homogeneous
Under the condition of (40-45) ℃, (18-20) MPa, carry out homogeneous, guarantee the homogeneity of product, improve the digestibility of product.
6, vacuum concentrates
Material behind the homogeneous enters cold boiler and reduces pressure concentratedly, removes Ruzhong most of moisture (about 65%), is beneficial to product quality and reduces production costs, economic benefits and social benefits sterilization temperature (80-83) ℃, 24 seconds time, material outlet concentration 16Be '.
7, spray-drying
150 ℃ of technological parameter EATs, 80 ℃ of temperature of outgoing airs, atomisation pressure (10-15) MPa.
8, sieve powder bean jelly
The milk powder that spray-drying is good should be sent the outer and cooling in time of hothouse rapidly, and the overlong time that keeps from heat influences product quality.The reciprocating sieve aerofoil can be separated big powder agglomates, with acquisition homogeneous granules milk powder, and the milk powder temperature is cooled to below 50 ℃.
9, the inspection of semifinished product
Powder after sieving carries out the semi-finished product sampling, carries out physics and chemistry and Micro biological Tests, enters next procedure under qualified situation.
10, Packing of Dried Milk
The Packing of Dried Milk technological process is:
Weighing → fill adds → exhaust → and seal → case → packaging and warehousing
11, product inspection
Finished product will carry out strict physics and chemistry and microbiological analysis, and leave the product report by the batch sampling of central laboratory.
12, the product accord with Q/WDS 045-2002 standard of dispatching from the factory, and have product return on qualification folk prescription to dispatch from the factory.
Happy milk powder aided blood pressure-lowering effect test is pressed in test one
1, material and method
1.1 sample: dairy industry limited company provides by the Wanda Mountain, Heilungkiang, it is off-white powder that the Wanda Mountain board is pressed happy milk powder, the human body recommended amounts is 50g/60kg BW/ day, the functional component that provides (hypotensive protein hydrolysate) is a white powder, be for experiment, its content in product is 10%, is equivalent to human body recommended amounts 5g/60kg BW/ day.
1.2 experimental animal: 40 of the spontaneous hypertension rats that provides by Chinese Academy of Medical Sciences's Experimental Animal Center, body weight: male 290 ± 20 grams, female 210 ± 20 grams, animal approval number SCXK11-00-0006.
1.3 instrument RBP-1 type rat blood pressure meter is by China-Japan Friendship Hospital's clinical research manufacturing.
1.4 experimental technique:
Room temperature remains on 22-24 ℃, with basal feed (being provided by Chinese Academy of Medical Sciences's Experimental Animal Center) raising rat.Observed 3 days before the experiment, measure blood pressure with the tail pulses method.Rat is fixed in 38 ℃ the insulating box, blood pressure and heart rate are measured in preheating 10 minutes.
Be divided into 3 dosage groups (0.42,0.84,1.68g/kg BW presses happy milk powder functional component, is equivalent to 5 times, 10 times, 20 times of human body recommended amounts respectively) and 1 control group, 10 every group, wherein male 4, female 6 at random according to the basic blood pressure value.Tried the thing water and be assigned to desired concn, irritate stomach and give rat, control group gives isopyknic water, irritates the stomach amount and presses 1ml/100g BW calculating, once a day, in continuous 4 weeks, measures blood pressure and heart rate weekly.
1.5 experimental data is set up database with EXCEL, carries out analyzing and processing with the STATA of statistical software.
2, result
2.1 ordinary circumstance and body weight:
In entire test, each treated animal well-grown is movable normal.By table 1 as seen, each dosage group body weight and weightening finish and control group comparing difference do not have conspicuousness (P＞0.05).
Table 1 is pressed the influence (g) of happy milk powder to the spontaneous hypertension rat body weight
| Dosage g/kg BW | Number of animals (only) | Body weight | Weightening finish | The P value | |||
| Before the test | The P value | The test end | The P value | ||||
| ??0.00 | ???10 | ??250.5±54.7 | ??- | ??261.0±57.0 | ??- | ??10.5±9.2 | ??- |
| ??0.42 | ???10 | ??250.7±53.6 | ??1.000 | ??257.5±51.0 | ??1.000 | ??6.8±9.2 | ??0.979 |
| ??0.84 | ???10 | ??243.8±54.8 | ??1.000 | ??256.2±58.6 | ??1.000 | ??12.5±7.1 | ??0.910 |
| ??1.68 | ????10 | ??248.2±54.8 | ??1.000 | ??257.4±65.8 | ??1.000 | ??9.2±13.2 | ??0.700 |
2.2 blood pressure:
By table 2 as seen, the blood pressure of comparing the 4th week 0.84,1.68g/kg BW dosage group with control group all reduces and difference has conspicuousness (P＜0.05), shows the blood pressure of pressing happy milk powder can reduce spontaneous hypertension rat, has the aided blood pressure-lowering effect.
Table 2 is pressed the influence (mmHg) of happy milk powder to the spontaneous hypertension rat blood pressure
| Dosage g/kg BW | Number of animals only | 0 week | 1 week | 2 weeks | |||
| Blood pressure | The P value | Blood pressure | The P value | Blood pressure | The P value | ||
| 0.00 | ??10 | ?201.6±13.6 | ?- | ?202.1±13.3 | ?- | ?203.7±14.1 | ?- |
| 0.42 | ??10 | ?202.7±15.0 | ?1.000 | ?199.0±14.0 | ?0.997 | ?199.1±15.4 | ?0.979 |
| 0.84 | ??10 | ?202.3±14.4 | ?1.000 | ?200.2±14.5 | ?1.000 | ?197.5±13.5 | ?0.910 |
| 1.68 | ??10 | ?202.1±14.2 | ?1.000 | ?195.8±14.8 | ?0.904 | ?195.1±13.9 | ?0.700 |
Continuous table 2
| Dosage g/kg BW | Number of animals only | 3 weeks | 4 weeks | ||
| Blood pressure | The P value | Blood pressure | The P value | ||
| 0.00 | ?10 | ?204.6±15.3 | ?- | ?207.3±14.1 | - |
| 0.42 | ?10 | ?195.8±13.5 | ?0.701 | ?194.8±13.4 | 0.186 |
| 0.84 | ?10 | ?196.9±14.2 | ?0.808 | ?189.9±12.8* | 0.024 |
| 1.68 | ?10 | ?192.5±14.9 | ?0.357 | ?190.0±10.0* | 0.025 |
* compare P＜0.05 with control group
2.3 heart rate:
By table 3 as seen, experimental session, the heart rate and the control group comparing difference that are tried the thing spontaneous hypertension rat do not have conspicuousness.
Table 3 presses happy milk powder to the influence of spontaneous hypertension rat heart rate (inferior/minute)
| Dosage g/kg BW | Number of animals only | 0 week | 1 week | 2 weeks | |||
| Heart rate | The P value | Heart rate | The P value | Heart rate | The P value | ||
| ??0.00 | ????10 | ?445.8±29.1 | ?- | ?443.6±25.6 | ?- | ?444.6±29.6 | ?- |
| ??0.42 | ????10 | ?454.2±24.4 | ?0.981 | ?445.6±27.4 | ?1.000 | ?446.7±26.1 | ?1.000 |
| ??0.84 | ????10 | ?453.4±28.5 | ?0.988 | ?444.2±25.6 | ?1.000 | ?443.1±26.8 | ?1.000 |
| ??1.68 | ????10 | ?451.7±23.2 | ?0.997 | ?442.6±21.5 | ?1.000 | ?441.0±24.6 | ?1.000 |
Continuous table 3
| Dosage g/kg BW | Number of animals only | 3 weeks | 4 weeks | ||
| Blood pressure | The P value | Blood pressure | The P value | ||
| ??0.00 | ????10 | ?439.7±30.8 | ??- | ??443.0±29.9 | ????- |
| ??0.42 | ????10 | ?440.5±31.2 | ??1.000 | ??444.7±35.8 | ????1.000 |
| ??0.84 | ????10 | ?440.4±24.0 | ??1.000 | ??439.2±29.3 | ????1.000 |
| ??1.68 | ????10 | ?440.8±24.3 | ??1.000 | ??438.9±30.6 | ????1.000 |
3 brief summaries
Irritate stomach every day and give continuous 4 weeks of the happy milk powder functional component of pressure of spontaneous hypertension rat 0.00,0.42,0.84,1.68g/kg BW, the result shows: compare with control group, the blood pressure of the 4th week 0.84,1.68g/kg BW dosage group all reduces, and difference has conspicuousness (P＜0.05); This sample does not have obvious influence to the heart rate and the body weight of spontaneous hypertension rat.The result shows, presses happy milk powder can reduce the blood pressure of spontaneous hypertension rat, and the aided blood pressure-lowering effect is arranged.
Happy milk powder toxicological safety test report is pressed in test two
1 material and method
1.1 sample: pressing happy milk powder is that the examination by sensory organs no abnormality seen is provided by Wanda Mountain, Heilungkiang dairy industry limited company.Consider its recommendation large usage quantity and the zooperal maximum stomach amount of irritating, so remove the security no problem in the sample that requires to provide but account for non-functional component milk powder, whey powder and the dextrine powder (account in the prescription gross weight 80%) of large percentage, only contain effect component and other adding ingredient (account in the prescription gross weight 20%), below all tests all use the sample that only contains effect component and other adding ingredient.
1.2 experimental animal: (approval card number: moving word 09-2-1 number of doctor), (the approval card number is Wistar strain big white mouse Kunming kind small white mouse: the moving word 09-3-2 of doctor) all available from institute of oncology, Heilongjiang Province Experimental Animal Center.
1.3 40 of Kunming kind small white mouses, male and female half and half, body weight 18.0-22.0g are selected in large and small mouse acute toxicity test for use; Be divided into 4 groups at random by sex, body weight, 5 every group, 40 of rats, male and female half and half, body weight 180-220g is divided into 4 groups at random by sex, body weight, 5 every group.
Carry out the dosage design by horn method, 4 dosage groups are respectively 2.15g/kg body weight, 4.64g/kg body weight, 10.0g/kg body weight and 21.5g/kg body weight (this dosage has reached 129 times of referrer's consumption per day).
Large and small mouse fasting was once irritated stomach (high dose group is for irritating stomach at interval in 6 hours at twice), the poisoning manifestations and the death condition of observing large and small mouse, 14 days observing times to animal by the 2% filling stomach volume per os that animal body is heavy after 16h hour.
1.4 genetic toxicity test
1.4.1 Salmonella reversion test TA97, TA98, TA100 and 4 kinds of bacterial strains of TA102 provide by California, USA university Ames Lab.The sample of removing milk powder, whey and dextrin is mixed with 5mg/0.1ml, 1mg/0.1ml, 0.2mg/0.1ml, 0.04mg/0.1ml and 0.008mg/0.1ml totally 5 concentration with sterile purified water.Except that above-mentioned 5 concentration groups, establish again from beaming back and become control group and positive control [adds S
9With 2-AF (TA
102With 1, the 8-istizin), do not add S
9With DEXON (TA
100Use Sodium azide)].Adopt flat board to mix the method test, every ware addition is 0.1ml.Each dosage is made 3 wares, and repeats once, reports twice result of the test respectively with 3 ware mean values at last.
1.4.2 PCEMNR micronucleus test Kunming kind small white mouse, body weight 25-30g, totally 50, male and female half and half.If 3 dosage groups, wherein high dose group is the 16.7g/kg body weight, is equivalent to 100 times of people's RD; Middle dosage group is the 8.3g/kg body weight, is equivalent to 50 times of people's RD; Low dose group is the 4.2g/kg body weight, is equivalent to 25 times of people's RD.All each groups are all irritated stomach by the 20ml/kg body weight.Adopt 30h to give the thing method of being tried, promptly for the first time to after being tried thing 24h, tried thing once more, mouse is put to death in the cervical vertebra dislocation behind the 6h, gets femur, conventional film-making.Every mouse of microscopically is observed 1000 polychromatic erythrocytes (PCE), and dosage has the cell number of micronucleus, calculates the micronucleus cell rate.
1.4.3 25 of Kunming kind male white mouses are selected in the mouse sperm deformity test for use, body weight 25.0-30.0g is divided into 5 groups at random, 5 every group.If 3 dosage groups, dosage designs with the mouse bone marrow cells micronucleus test, that is: high dose group is the 16.7g/kg body weight, and middle dosage group is the 8.3g/kg body weight, and low dose group is the 4.2g/kg body weight.Negative control group gives distilled water, and positive controls gives endoxan, and dosage is the 40mg/kg body weight.All each groups are all irritated stomach by the 20ml/kg body weight.Once a day, continuous 5 days.Each treated animal all in throw first with sample after put to death in 35 days, film-making according to a conventional method, fixing, 2% Yihong solution-dyed, 1000 complete sperms of every mouse microscopy calculate rate of teratosperm.
1.5 30 days feeding trials
Just the Wistar rat of ablactation is 80, and body weight 60-80g is divided into 4 groups at random, and 20 every group, male and female half and half, wherein three groups is test group, one group is control group.
Requiring high dose according to toxicology test should be 100 times of people's RD, and client's RD is 50g/d, becomes body weight for humans as in 60kg, then is the 83.3g/kg body weight.The animal food-intake weighs 10% (being that rat is taken in the 100g feed by every kg body weight) by animal body, 83.3g should be incorporated in the 100g feed by the design's requirement, and the content that sample accounts for feed is 83.3%; If with removing that milk powder, whey powder and dextrin grade non-functional component and the part (account in the prescription gross weight 20%) that only contains the effect component is mixed and tested in the feed, still be 16.7%.Mix the proportion requirement of forage volume according to the toxicology test sample, thus be not suitable for mixing in the feed, so select for use the per os administration by gavage to give given the test agent to throwing.Dosage design is as follows: high dose is 17.7g/kg body weight (is equivalent to the people and recommends 100 times of consumption), and middle dosage is 8.3g/kg body weight (be equivalent to the people and recommend 50 times of consumption), and low dosage is 4.2g/kg body weight (is equivalent to the people and recommends 25 times of consumption).
Experimental animal is irritated the stomach throwing by the filling stomach volume per os of 20ml/kg body weight and is given given the test agent; Negative control is irritated isometric clean water.Irritate stomach every day once, continuous irrigation stomach 30 days.
Observe and write down general situation, poisoning symptom and the death condition of animal every day.Claim body weight weekly one time, write down total food ration of every treated animal, and, calculate food utilization according to weightening finish in 30 days and food ration.When experiment finished, blood sampling detected hematological indices, and the check biochemical indicator, as glutamic-pyruvic transaminase (ALT), and glutamic-oxalacetic transaminease (AST), total protein (TP), albumin (ALB), urea nitrogen (BUN), blood sugar (GLU), cholesterol (TC) and inosine (Cr).Cut rat abdomen simultaneously open, taking-up liver,kidney,spleen, testis, ovary are weighed, and calculate dirty/body ratio, and carry out pathological examination.
1.6 selecting for use the SYSTAT statistical software to carry out statistical methods such as Poisson distribution, variance analysis, X2 check and mean t check to test data, the data processing carries out statistical analysis.
2 results
2.1 acute toxicity test
Result of the test sees Table 4 and table 5.
Table 4 is pressed the acute toxicity of happy milk powder to mouse
| Animal varieties | Sex | Quantity | Approach | Dosage (g/kg.bw) | Death condition | Conclusion |
| Mouse | Male | 5 | Per os | 2.15 | Do not have | True border innocuous substance |
| 5 | Per os | 4.64 | Do not have | |||
| 5 | Per os | 10.0 | Do not have | |||
| 5 | Per os | 21.5 | Do not have | |||
| Mouse | Female | 5 | Per os | 2.15 | Do not have | True border innocuous substance |
| 5 | Per os | 4.64 | Do not have | |||
| 5 | Per os | 10.0 | Do not have | |||
| 5 | Per os | 21.5 | Do not have |
Table 5 is pressed the acute toxicity of happy milk powder to rat
| Animal varieties | Sex | Quantity | Approach | Dosage (g/kg.bw) | Death condition | Conclusion |
| Rat | Male | 5 | Per os | 2.15 | Do not have | True border innocuous substance |
| 5 | Per os | 4.64 | Do not have | |||
| 5 | Per os | 10.0 | Do not have | |||
| 5 | Per os | 21.5 | Do not have | |||
| Rat | Female | 5 | Per os | 2.15 | Do not have | True border innocuous substance |
| 5 | Per os | 4.64 | Do not have | |||
| 5 | Per os | 10.0 | Do not have | |||
| 5 | Per os | 21.5 | Do not have |
In 14 days viewing duration, tried large and small mouse and poisoning symptom all do not occurred, the dead generation also do not arranged, the animal general state is good.Dosage, observed result and the large and small mouse acute toxicity criterion designed according to test can be thought and press the true border of happy milk powder innocuous substance.
2.2 genetic toxicity test
2.2.1 Salmonella reversion test
Press happy milk powder Salmonella reversion test result to see Table 6 and table 7 respectively.
Table 6 is pressed happy milk powder Salmonella reversion test result (for the first time)
| Dosage (mg/ ware) | TA?97 | ?TA?98 | ?TA?100 | ?TA?102 | |||||
| -S9 | ?+S9 | ?-S9 | ?+S9 | ?-S9 | ?+S9 | ?-S9 | ?+S9 | ||
| Tried thing | 5 | 132±24 | ?150±2 | ?50±1 | ?50±13 | ?138±10 | ?147±8 | ?266±13 | ?297±21 |
| 1 | 147±6 | ?150±15 | ?48±5 | ?48±10 | ?160±4 | ?163±22 | ?282±35 | ?305±8 | |
| 0.2 | 149±20 | ?152±23 | ?46±6 | ?45±10 | ?141±13 | ?145±10 | ?267±4 | ?240±33 | |
| 0.04 | 141±3 | ?142±6 | ?34±3 | ?46±2 | ?152±4 | ?142±14 | ?263±8 | ?277±18 | |
| 0.008 | 153±15 | ?148±9 | ?44±6 | ?40±7 | ?143±12 | ?144±7 | ?262±30 | ?290±8 | |
| From beaming back change | 145±4 | ?154±35 | ?47±25 | ?38±6 | ?142±6 | ?145±4 | ?280±33 | ?270±18 | |
| Positive control (μ g/ ware) | |||||||||
| 2-AF | 10.0 | ?1285±1 ?9 | ?1144±2 ?8 | ?1458±8 ?0 | |||||
| 1, the 8-istizin | 50.0 | ?844±20 | |||||||
| Sodium azide | 1.5 | ?1344±7 ?7 | ?1108±7 ?4 | ||||||
| DEXON | 60.0 | 1269±2 45 | ?1012±5 ?.7 | ||||||
Table 7 is pressed happy milk powder Salmonella reversion test result (for the first time)
| Dosage (mg/ ware) | TA?97 | ?TA?98 | ?TA?100 | ?TA?102 | |||||
| ?-S9 | ?+S9 | -S9 | ?+S9 | ?-S9 | ?+S9 | ?-S9 | ?+S9 | ||
| Tried thing | ?5 | ?143±9 | ?131±9 | ?45±2 | ?39±2 | ?125±8 | ?131±7 | ?247±22 | ?238±14 |
| ?1 | ?148±4 | ?139±19 | ?43±4 | ?39±6 | ?126±19 | ?132±8 | ?247±6 | ?256±4 | |
| ?0.2 | ?152±12 | ?146±19 | ?45±3 | ?39±2 | ?135±7 | ?139±12 | ?244±3 | ?270±21 | |
| ?0.04 | ?148±5 | ?160±16 | ?45±5 | ?40±3 | ?135±8 | ?124±6 | ?261±3 | ?279±21 | |
| ?0.008 | ?145±8 | ?168±3 | ?42±5 | ?39±4 | ?128±13 | ?125±6 | ?266±8 | ?275±12 | |
| From beaming back change | ?145±8 | ?152±10 | ?40±7 | ?43±5 | ?131±12 | ?125±7 | ?256±69 | ?258±15 | |
| Positive control (μ g/ ware) | |||||||||
| 2-AF | ?10.0 | ?1258±68 | ?1101±89 | ?1404±17 | |||||
| 1, the 8-istizin | ?50.0 | ?868±79 | |||||||
| Sodium azide | ?1.5 | ?1367±5 ?5 | |||||||
| ?DEXON | ?60.0 | ?1249±3 ?49 | ?966± ?24 | ?1302±1 ?87 | |||||
Annotate: above result is three ware mean values.
Result of the test shows, is subjected to the sample product to press happy milk powder adding and do not adding under S9 (hepatomicrosome enzyme) activation condition, and to the Salmonella reversion test bacterial strain result that all is negative, promptly the Salmonella reversion test result is the mutagenesis feminine gender.
2.2.2 PCEMNR micronucleus test
Press happy milk powder that the PCEMNR micronucleus test be the results are shown in Table 8.
Table 8 is pressed the influence of happy milk powder to the mouse bone marrow cells microkernel incidence
| Sex | Dosage (g/kg.bw) | Number of animals (only) | Check cell number (individual) | Micronucleus number (individual) | Micronuclear rates (‰) |
| Male | 16.7 | 5 | ?5000 | ?6 | ?1.2 |
| 8.3 | 5 | ?5000 | ?7 | ?1.4 | |
| 4.2 | 5 | ?5000 | ?9 | ?1.8 | |
| Negative control | 5 | ?5000 | ?6 | ?1.2 | |
| Positive control | 5 | ?5000 | ?88 | ?17.6 | |
| Female | 16.7 | 5 | ?5000 | ?6 | ?1.2 |
| 8.3 | 5 | ?5000 | ?7 | ?1.4 | |
| 4.2 | 5 | ?5000 | ?9 | ?1.8 | |
| Negative control | 5 | ?5000 | ?7 | ?1.4 | |
| Positive control | 5 | ?5000 | ?109 | ?21.8 |
Result of the test is carried out Poisson distribution check, and two sex mouse of result are except that positive controls, and each dosage group is compared with the negative control group micronuclear rates, and equal no significant differences illustrates that the mouse bone marrow cells of being tried thing has a liking for the negative result of polychromatophilia micronucleus test.
2.2.3 mouse sperm deformity test test
Press the mouse sperm deformity test result of the test of happy milk powder to see Table 9.
Table 9 is pressed the influence of happy milk powder to the mouse sperm deformity incidence
| Dosage (g/kg.bw) | Number of animals (only) | Examined sperm count (individual) | Teratospermia number (individual) | Rate of teratosperm (%) |
| 16.7 | 5 | ?5000 | ?89 | ?1.8 |
| 8.3 | 5 | ?5000 | ?91 | ?1.8 |
| 4.2 | 5 | ?5000 | ?78 | ?1.6 |
| Negative control | 5 | ?5000 | ?67 | ?1.3 |
| Positive control | 5 | ?5000 | ?280 | ?5.6 |
As seen from Table 9, each organizes mouse all can see the defective sperm of some, but the positive controls rate of teratosperm that changes phosphamide compares with negative control group, and utmost point significant difference (P＜0.01) is arranged; And the rate of teratosperm of each test group mouse is compared with negative control group, and there are no significant (P＞0.05), illustrates that being tried thing does not have the mouse sperm deformity incidence and influence.
2.3 30 days feeding trials
In entire test, each treated animal does not see that animal subject has any tangible bad reaction generally in order, more not having the generation that causes death of poisoning.
2.3.1 influence to rat body weight
In 30 days nursing processes, press happy milk powder that the influence of rat body weight weightening finish is seen Table 10.
Table 10 is pressed the influence of happy milk powder to rat body weight
| Sex | Dosage (g/kg.bw) | Number of animals (only) | Starting weight | The 1st week | The 2nd week | The 3rd week | The 4th week |
| Male | 16.7 | ?10 | ?73.3±6.8 | ?107.2±8.0 | ?135.8±8.9 | ?168.1±13.8 | ?207.8±21.6 |
| 8.3 | ?10 | ?74.1±6.7 | ?105.0±9.4 | ?142.6±15.1 | ?180.6±19.5 | ?216.9±25.1 | |
| 4.2 | ?9 | ?74.2±6.2 | ?111.7±7.4 | ?145.7±7.0 | ?180.7±8.8 | ?223.0±13.3 | |
| Negative control | ?10 | ?73.5±7.0 | ?111.0±7.5 | ?139.0±10.7 | ?176.0±11.6 | ?208.4±12.6 | |
| Female | 16.7 | ?10 | ?74.7±5.8 | ?105.9±11.6 | ?130.9±15.4 | ?158.9±22.9 | ?188.1±24.1 |
| 8.3 | ?10 | ?78.1±3.2 | ?112.5±8.6 | ?139.9±9.2 | ?167.2±10.4 | ?195.8±10.8 | |
| 4.2 | ?10 | ?78.0±2.4 | ?108.4±10.1 | ?132.9±14.4 | ?160.6±14.6 | ?186.7±11.6 | |
| Negative control | ?10 | ?77.2±5.0 | ?109.8±12.6 | ?138.5±15.7 | ?169.7±16.9 | ?194.3±20.0 |
His-and-hers watches 10 rat body weights carry out variance analysis to be handled, and result's there are no significant difference (P＞0.05) illustrate that the happy milk powder of pressure has no adverse effects to the growth of rat body weight.
2.3.2 influence to rat total foodstuff utilization rate
Press happy milk powder that the influence of rat total foodstuff utilization rate is seen Table 11.
Table 11 is pressed the influence of happy milk powder to rat total foodstuff utilization rate
| Sex | Dosage (g/kg.bw) | Number of animals (only) | Weight gain | Food-intake (g) | Food utilization % | F | The P value |
| Male | 16.7 | ?10 | ?134.5±20.6 | ?539.0±31.7 | ?25.0±4.2 | 1.543 | 0.221 |
| 8.3 | ?10 | ?142.8±22.0 | ?519.4±29.2 | ?27.4±3.2 | |||
| 4.2 | ?9 | ?148.8±15.4 | ?545.0±30.7 | ?27.3±1.9 | |||
| Negative control | ?10 | ?134.9±12.5 | ?541.5±44.0 | ?25.1±3.5 | |||
| Female | 16.7 | ?10 | ?113.4±21.6 | ?474.5±42.0 | ?23.7±3.0 | 0.629 | 0.601 |
| 8.3 | ?10 | ?117.7±11.8 | ?489.1±24.9 | ?24.1±1.9 | |||
| 4.2 | ?10 | ?108.7±10.7 | ?478.2±36.8 | ?22.8±2.2 | |||
| Negative control | ?10 | ?117.1±19.4 | ?501.0±32.7 | ?23.3±2.8 |
The food utilization of his-and-hers watches 11 carries out variance analysis, and there was no significant difference (P＞0.05) between each group illustrates and presses happy milk powder that the total foodstuff utilization rate of rat is not had obvious influence.
2.3.3 hematological examination result
Rat hemoglobin and leukocytic testing result see Table 12.
Table 12 presses happy milk powder rat blood to be learned the influence of index
| Sex | Group | Dosage (g/kg) | WBC sum (10 9/L) | WBC classify (%) | ?Hb ?(g/L) | |||
| ?L | ?N | ?E | ?M | |||||
| Male | High dose group | 83.3 | 15.3±1.4 | ?78.2 | ?21.3 | ?0.3 | ?0.2 | ?122.0±8.6 |
| Middle dosage group | 41.7 | 15.2±1.0 | ?78.0 | ?21.3 | ?0.4 | ?0.3 | ?122.5±7.9 | |
| Low dose group | 20.8 | 14.2±1.2 | ?79.3 | ?20.0 | ?0.6 | ?0.1 | ?123.3±7.9 | |
| Control group | 0 | 15.6±1.6 | ?79.4 | ?19.9 | ?0.5 | ?0.2 | ?120.5±10.1 | |
| Female | High dose group | 83.3 | 15.0±1.6 | ?79.2 | ?19.0 | ?1.2 | ?0.6 | ?124.0±4.6 |
| Middle dosage group | 41.7 | 14.5±2.3 | ?80.8 | ?17.7 | ?1.4 | ?0.1 | ?125.0±6.2 | |
| Low dose group | 20.8 | 14.6±2.5 | ?79.7 | ?19.2 | ?1.0 | ?0.1 | ?122.0±7.5 | |
| Control group | 0 | 15.0±1.3 | ?81.1 | ?17.9 | ?0.7 | ?0.3 | ?126.5±8.2 | |
As seen from Table 12, each dosage treated animal total white blood cells, leukocyte differential count and content of hemoglobin are all in normal range (NR), and each dosage group compares no conspicuousness difference with control group, illustrate and press happy milk powder that the above-mentioned hematological indices of rat is not had influence.
2.3.4 biochemical investigation in latter stage result
Put to death animal after the off-test, separate rat blood serum, carry out the detection of the indexs such as activity, total protein (TP), albumin (ALB), urea nitrogen (BUN), blood sugar (GLU), cholesterol (TC) and inosine (Cr) content of serum glutamic oxalacetic transaminase (AST) and glutamate pyruvate transaminase (ALT), the results are shown in Table 13.
Table 13 is pressed the influence of happy milk powder to rat biochemical result in latter stage
| Sex | Dosage (g/kg.bw) | ?ALT(IU/L) | ??AST(IU/L) | ??BUN ?(mmol/L) | TP(g/L) | ?ALB ?(g/L) | ?GLU ?(mmol/L) | ?TC ?(mmol/L) | ?Cr ?(μmol/L) |
| Male | 16.7 | ?42.4±4.6 | ?165.4±27.3 | ?6.9±1.7 | ?60.8±3.0 | ?39.7±3.5 | ?6.2±1.1 | ?1.7±0.11 | ?64.3±16.0 |
| 8.3 | ?39.7±0.9 | ?172.2±28.5 | ?6.4±1.2 | ?62.4±3.6 | ?36.7±5.4 | ?6.6±0.9 | ?1.7±0.08 | ?66.7±15.9 | |
| 4.2 | ?39.1±1.7 | ?157.1±20.6 | ?6.4±1.9 | ?61.4±0.8 | ?38.1±2.7 | ?6.4±0.8 | ?1.7±0.10 | ?78.9±14.2 | |
| Negative control | ?42.4±3.9 | ?150.8±29.1 | ?6.6±1.3 | ?60.9±1.1 | ?37.9±2.6 | ?6.7±0.8 | ?1.7±0.10 | ?61.7±15.4 | |
| Female | 16.7 | ?39.1±5.1 | ?146.1±28.1 | ?6.3±1.3 | ?62.9±1?9 | ?40.8±3.5 | ?6.8±0.7 | ?1.7±0.09 | ?60.6±15.8 |
| 8.3 | ?37.9±2.5 | ?141.6±15.3 | ?6.3±2.0 | ?63.7±2.6 | ?41.4±1.9 | ?6.8±1.0 | ?1.7±0.08 | ?67.5±18.6 | |
| 4.2 | ?39.1±2.1 | ?159.2±23.1 | ?6.6±1.8 | ?59.4±3.2 | ?41.5±2.4 | ?6.8±0.8 | ?1.7±0.09 | ?61.4±17.6 | |
| Negative control | ?40.7±6.3 | ?168.3±35.6 | ?6.4±1.6 | ?61.4±0.9 | ?36.2±4.4 | ?6.6±0.9 | ?1.7±0.07 | ?60.1±10.6 |
His-and-hers watches 13 results carry out variance analysis, and the result shows, and each treated animal is dirty/and body is than there was no significant difference (P＞0.05).
Histopathologic examination: the histopathologic examination that each organizes the rat main organs there is no tangible Histopathology and changes.Each treated animal liver tunicle is complete, is leaflet structure, does not have downright bad, hemorrhage and the inflammatory cell infiltration change; Each treated animal kidney cortex and medullary substance structure are clear, and glomerulus and renal tubule structure are normal, do not see necrosis, hemorrhage and inflammatory change; Other internal organs are not also seen pathological change.Illustrate and press happy milk powder that main organs such as rat liver,spleen,kidney, testis, ovary are not had the damage effect.
3 brief summaries
Tried thing and pressed the true border of happy milk powder per os acute toxicity innocuous substance; Three genetic toxicity tests such as Salmonella reversion test, PCEMNR micronucleus test, mouse sperm deformity test detect and are negative findings; 30 days feeding trials also do not see that it has any toxicity damage effect to animal subject.
Claims (5)
1, a kind of with health role, especially regulate the powdered milk composition of blood pressure effect, be characterised in that to comprise:
Fresh milk 260～720 weight portions
Hypotensive protein hydrolysate 0.1～40 weight portion
Vitamin E 0.001～0.05 weight portion
Whey powder 0～30 weight portion
Dextrine powder 0～20 weight portion
Maltose 0～10 weight portion
Refined oil 0～5 weight portion
Palm oil 0～5 weight portion
Calcium powder 0～5 weight portion
Potassium citrate 0～10 weight portion
Vitamin and trace element 0～an amount of
FOS (clean thing) 0～2 weight portion
Perhaps above-mentioned fresh milk can replace with 30-80 weight portion milk powder.
2, according to the powdered milk composition of claim 1, comprising:
Fresh milk 260～720 weight portions
Hypotensive protein hydrolysate 1～20 weight portion
Vitamin E 0.1～0.03 weight portion
Whey powder 0～30 weight portion
Dextrine powder 0～20 weight portion
Maltose 0～10 weight portion
Refined oil 0～5 weight portion
Palm oil 0～5 weight portion
Calcium powder 0～5 weight portion
Potassium citrate 0～10 weight portion
Vitamin and trace element are an amount of
FOS (clean thing) 0.01～2 weight portion
Perhaps above-mentioned fresh milk can replace with 30-80 weight portion milk powder.
3, according to the powdered milk composition of claim 1 or 2, wherein hypotensive protein hydrolysate is to carry out enzyme hydrolysis by casein and/or lactalbumin, the peptide of the biologically active that obtains--blood pressure lowering peptide.
4, according to the powdered milk composition of claim 1 or 2, wherein hypotensive protein hydrolysate comprise following polypeptide one or more or all:
Ser-Ala-Pro, Met-Lys-Gly, Ala-Leu-Pro-Met-His, Leu-Ile-Val-Thr-Gln, Val-Ser-Leu-Pro-Glu-Trp, Ile-Asp-Tyr-Trp-Leu, Leu-Lys-Pro-Thr-Pro-Glu-Gly-Asp-Leu-Glu-Ile-Leu, and Leu-Lys-Gly-Tyr-Gly-Gly-Val-Ser-Leu-Pro-Glu-Ser.
5, according to the preparation method of the powdered milk composition of claim 1 or 2, comprise raw material cow's milk is purified that various raw materials are allocated in the preheating sterilization, homogeneous, vacuum concentrates, spray-drying, cooling and packing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA03100380XA CN1517026A (en) | 2003-01-16 | 2003-01-16 | Milk powder capable of regulating blood pressure |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA03100380XA CN1517026A (en) | 2003-01-16 | 2003-01-16 | Milk powder capable of regulating blood pressure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1517026A true CN1517026A (en) | 2004-08-04 |
Family
ID=34281150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA03100380XA Pending CN1517026A (en) | 2003-01-16 | 2003-01-16 | Milk powder capable of regulating blood pressure |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1517026A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102125097A (en) * | 2010-12-30 | 2011-07-20 | 陈慧婷 | Formula and preparation method of milk powder for improving women anemia |
| CN102885138A (en) * | 2012-09-29 | 2013-01-23 | 黑龙江省完达山乳业股份有限公司 | Powder composition with cholesterol-removing cardiovascular-dredging function formula and preparation method thereof |
| CN107712064A (en) * | 2016-08-11 | 2018-02-23 | 宏乐集团有限公司 | A kind of formula peptide milk powder with whitening function of reducing weight and preparation method thereof |
| CN110615827A (en) * | 2019-09-10 | 2019-12-27 | 中国海洋大学 | X-Pro structure specific ACE inhibitory peptide and preparation method thereof |
| CN112546200A (en) * | 2019-09-25 | 2021-03-26 | 安徽顶呱呱食品有限公司 | Protein composition for assisting in reducing blood pressure |
| CN112753773A (en) * | 2019-11-11 | 2021-05-07 | 东北农业大学 | Cow milk formula milk powder capable of reducing blood pressure and preparation method thereof |
-
2003
- 2003-01-16 CN CNA03100380XA patent/CN1517026A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102125097A (en) * | 2010-12-30 | 2011-07-20 | 陈慧婷 | Formula and preparation method of milk powder for improving women anemia |
| CN102885138A (en) * | 2012-09-29 | 2013-01-23 | 黑龙江省完达山乳业股份有限公司 | Powder composition with cholesterol-removing cardiovascular-dredging function formula and preparation method thereof |
| CN107712064A (en) * | 2016-08-11 | 2018-02-23 | 宏乐集团有限公司 | A kind of formula peptide milk powder with whitening function of reducing weight and preparation method thereof |
| CN110615827A (en) * | 2019-09-10 | 2019-12-27 | 中国海洋大学 | X-Pro structure specific ACE inhibitory peptide and preparation method thereof |
| CN112546200A (en) * | 2019-09-25 | 2021-03-26 | 安徽顶呱呱食品有限公司 | Protein composition for assisting in reducing blood pressure |
| CN112753773A (en) * | 2019-11-11 | 2021-05-07 | 东北农业大学 | Cow milk formula milk powder capable of reducing blood pressure and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1794925A (en) | Novel nutraceutical compositions and use thereof | |
| CN1875752A (en) | Flour composition with increased total dietary fiber, process of making, and uses thereof | |
| CN1044659A (en) | Whey protein composition, the application of its production method and whey protein composition | |
| CN1694695A (en) | Novel nutraceutical compositions comprising epigallocatechin gallate | |
| CN1307478A (en) | Food composition and method of using same | |
| CN1806621A (en) | Liquid milk | |
| CN1200614C (en) | Canine health diet | |
| CN1920049A (en) | Small molecule bioactive peptide, preparation method, composition and application thereof | |
| CN1517026A (en) | Milk powder capable of regulating blood pressure | |
| EP3199032B1 (en) | Method of feeding calves with high protein milk replacers containing non-milk proteins | |
| CN1383426A (en) | Obesity inhibitory materials | |
| CN1167459C (en) | Nutritive health food with functions of reducing blood fat and delaying senility and its prepn process | |
| CN1678327A (en) | Use of hesperidin or one of its derivatives for making a medicine for bone formation stimulation | |
| CN1476830A (en) | Tea-polyphenol soft capsule and its preparation process | |
| CN1883527A (en) | A health product of lucid ganoderma and preparation method thereof | |
| CN108251485A (en) | A kind of functionality mixed plant peptide and its application | |
| CN1115967C (en) | High energy biscuit and its production process | |
| CN1736222A (en) | Blood sugar reducing or keeping milk powder and preparation process thereof | |
| CN1843135A (en) | Coagulated sheep milk tea powder | |
| CN1511443A (en) | Method for cultivating Bailing mushroom and Disease prevention improver containing Bailing mushroom | |
| CN1383380A (en) | Stem cell reinforcing material | |
| CN1062762A (en) | Fermentative activity enhanced cell goods preparation method and application based on vegetable cell | |
| CN1102061C (en) | Enqlish yew-manna tea | |
| CN1822879A (en) | Use of whey permeate for the treatment of metabolic syndrome | |
| CN1658766A (en) | Process for producing lacturose-containing powder composition, lacturose-containing powder composition obtained by the process and feed additive |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |